Cytomegalovirus

Select type 1 IFNs may act as natural adjuvants for anti-CMV immune response

Published in Vaccine Weekly, December 25th, 2002

Coimmunization of type 1 IFN and glycoprotein B cytomegalovirus (CMV) DNA constructs was shown to enhance protective immunity in mice, researchers in Australia report.

"Viral DNA vaccines encoding the glycoprotein B (gB) of cytomegalovirus provide partial protective immunity upon challenge with infectious virus. Although it is known that type 1 IFN can stimulate the adaptive immune response, their direct use in vaccines has been limited," said V.S. Cull and colleagues, Murdoch University, Perth.

They reported that in their study, "in vivo expression of IFN transgenes ranged from 1.2 to 2.0 x 10⁴, IU/g tibialis anterior muscle. Viral...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry